ARTHEx Biotech to Present at the 25th Virtual Healthcare Conference with a Focus on RNA Therapeutics

ARTHEx Biotech Participates in Needham Virtual Healthcare Conference

ARTHEx Biotech, a clinical-stage biotechnology company devoted to developing RNA-based therapeutic solutions for neuromuscular disorders, has proudly announced its involvement in the 25th Annual Needham Virtual Healthcare Conference. This esteemed event, scheduled from April 13 to 16, 2026, serves as an excellent platform for the company to share insights with potential investors about its groundbreaking projects and future ambitions.

About the Conference

The Needham Virtual Healthcare Conference is renowned for facilitating discussions between innovative healthcare companies and investors aiming to understand emerging trends in biotechnology, pharmaceuticals, and healthcare solutions. During this conference, ARTHEx Biotech's management will engage in one-on-one meetings to showcase their innovative work in RNA therapeutics.

Company Overview

ARTHEx Biotech focuses on developing RNA-targeted medicines that are designed to precisely modulate gene expression. Leveraging its proprietary BOOST-ONÔ platform, the company aims to deliver selective oligonucleotides directly to affected tissues such as skeletal muscle, heart, and brain. This specificity is crucial for treating conditions like myotonic dystrophy type 1 (DM1), which is the lead focus for clinical evaluation through their ArthemiR™ trial.

Pipeline Development

The company's lead candidate, ATX-01, is currently undergoing clinical evaluation as part of a Phase I/IIa trial aimed at providing targeted therapy for DM1, a rare but impactful neuromuscular disorder. The results from this trial could substantially transform treatment protocols for patients suffering from this condition. Additionally, ARTHEx Biotech is exploring other high unmet needs related to muscular, central nervous system (CNS), and cardiac diseases to expand its therapeutic pipeline.

Commitment to Innovation

Headquartered in Valencia, Spain, ARTHEx Biotech is positioned to take the lead in the sector of RNA-based therapeutics through continuous innovation and research. The company is steadfast in its mission to advance healthcare by developing treatments that can fundamentally change the lives of patients with neuromuscular disorders.

For more information on ATX-01, please visit clinicaltrials.gov or explore the company's comprehensive offerings by visiting www.arthexbiotech.com. You can also follow the company on LinkedIn to stay updated with their latest developments and announcements.

Conclusion

ARTHEx Biotech's participation in the Needham Virtual Healthcare Conference demonstrates its dedication to pushing the boundaries of biotechnology and improving health outcomes for individuals with neuromuscular disorders. The insights shared during this conference are expected to engage stakeholders further in the company's journey toward delivering innovative RNA-based therapies.